Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) — The “Therapies for Rheumatoid Arthritis: Technologies and Global Markets” report has been added to ResearchAndMarkets.com’s offering.
The global market for rheumatoid arthritis therapies was valued at $28.5 billion in 2024 and is estimated to increase from $30.2 billion in 2025 to reach $41.1 billion by 2030, at a compound annual growth rate (CAGR) of 6.3% from 2025 through 2030.
The current report will provide detailed information on therapies for rheumatoid arthritis (RA). This report analyzes the market trends of RA therapies, with the base year for the study set at 2024, estimated for 2025, and forecast between 2026 and 2030, including compound annual growth rate (CAGR) for the forecast period and regional markets.
The World Health Organization (WHO) has identified RA as a chronic, systemic inflammation that affects joints and causes pain. It can damage surrounding tissues, the heart, lungs, and the nervous system. Symptoms include persistent pain, stiffness, tenderness, warmth, and swelling, which can limit mobility and daily function. Proper management is crucial.
According to Austin, L. et al. (2020), the REMORA (Remote Monitoring of Rheumatoid Arthritis) study has shown a significant correlation between remote monitoring of RA and decreased disease activity. Similarly, according to Arthritis and Rheumatology (2023), electronic patient outcome measures (ePROMs), deployed through mobile applications and web pages, provide a more comprehensive understanding of RA by capturing the dynamic nature of symptoms like pain, joint swelling, and fatigue. ePROMs foster meaningful patient-physician interactions, enhancing understanding and collaboration while boosting patient confidence and satisfaction. They facilitate a deeper exploration of emotional well-being and coping mechanisms.
According to the Arthritis Foundation, approximately 1.5 million individuals in the U.S. are affected by RA. Women are three times more likely to develop RA than men, with onset typically occurring between ages 30 and 60. RA is uncommon in men under 45. RA treatment is significantly improved by integrating smart technologies like smartphones, smartwatches, and wearables. These offer significant avenues for digital self-management, clinical decision-making, sensor-based tracking, and digital behavior change interventions
Report Includes
94 data tables and 51 additional tablesIn-depth analysis of the global markets for rheumatoid arthritis (RA) treatment therapiesAnalyses of global market trends, with revenue data for 2024, estimates for 2025, forecasts for 2026, and projected CAGRs through 2030Estimates of the market’s current size and revenue prospects, accompanied by a market share analysis based on therapy type, sales channel and regionFacts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factorsInsights derived from Porter’s Five Forces model, as well as global supply chain analysisDiscussion of the key marketed products and products in different stages of clinical developmentAn analysis of patents, and emerging trends and developments in patent activityOverview of sustainability trends and ESG developments, with consumer attitudes, and the ESG scores and practices of leading companiesAnalysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlookCompany profiles of major players within the industry, including AbbVie Inc., Pfizer Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Co., Amgen Inc., and F. Hoffmann-La Roche Ltd.
The report aims to:
Analyze RA therapy types.Analyze global market size and segmentation.Understand market constraints and drivers.Provide detailed market forecasts for 2030.Assess market shares, competitiveness, and industry structure.Identify potential long-term impacts on the market for RA therapies.
Key Attributes:
Report AttributeDetailsNo. of Pages184Forecast Period2025 – 2030Estimated Market Value (USD) in 2025$30.2 BillionForecasted Market Value (USD) by 2030$41.1 BillionCompound Annual Growth Rate6.3%Regions CoveredGlobal
Key Topics Covered:
Chapter 1 Executive Summary
Market OutlookScope of ReportMarket Summary
Chapter 2 Market Overview
OverviewMacroeconomic Factor AnalysisImpact of U.S. Tariffs on the Pharmaceutical IndustryAging PopulationGeopolitical Risks, Trade Wars, and Supply Chain DisruptionsIncreasing Healthcare ExpendituresPorter’s Five Forces Analysis
Chapter 3 Market Dynamics
Market DynamicsMarket DriversIncreasing Biosimilars for RA TreatmentRising Cases of RAIncreasing Aging PopulationMarket RestraintsLoss of Patent ExclusivityShortage of RheumatologistsSide Effects of RA DrugsMarket OpportunitiesTechnological Advances in RA TherapiesEmerging Targeted TherapiesIncreasing Inorganic Strategies amongst Manufacturers
Chapter 4 Regulatory Landscape
OverviewThe U.S.BiologicsBiosimilarsEuropeAsia-Pacific
Chapter 5 Emerging Technologies and Pipeline Analysis
OverviewArtificial Intelligence (AI) and Machine Learning (ML)Stem Cell TherapyImmunotherapyPipeline AnalysisPatent AnalysisKey Takeaways
Chapter 6 Market Segmentation Analysis
Segmentation BreakdownGlobal Market for RA Therapies by Therapy TypeKey TakeawaysDisease-modifying Anti-rheumatic Drugs (DMARDs)Targeted Synthetic DMARDs/JAK InhibitorsNon-steroidal Anti-Inflammatory Drugs (NSAIDs)BiosimilarsSteroidsOther DrugsGlobal RA Therapies by Sales ChannelKey TakeawaysPrescription DrugsOver-the-Counter (OTC) DrugsGeographic BreakdownGlobal Market for RA Therapies, by RegionKey TakeawaysNorth AmericaEuropeAsia-PacificMiddle East and Africa (MEA)South America
Chapter 7 Competitive Intelligence
Key TakeawaysMarket Share AnalysisCompany Share Analysis
Chapter 8 Sustainability in the RA Therapies Market: An ESG Perspective
Introduction to ESGSustainability in the Market for RA TherapiesESG PerspectiveEnvironmental ImpactSocial ImpactGovernance ImpactESG Risk RatingsConclusion
Chapter 9 Appendix
Company Profiles
AbbottAbbvie Inc.Amgen Inc.Bayer AgBristol-Myers Squibb Co.F. Hoffmann-La Roche Ltd.Gilead Sciences Inc.Gsk Plc.Johnson & Johnson Services Inc.LillyPfizer Inc.SanofiSwedish Orphan Biovitrum AbTeva Pharmaceutical Industries Ltd.Viatris Inc.
For more information about this report visit https://www.researchandmarkets.com/r/bb2nc5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Therapies for Rheumatoid Arthritis Market
